Bio Products Laboratory

Last updated

Bio Products Laboratory Limited
Company typeSubsidiary
Industry Healthcare
Founded1954;70 years ago (1954)
Headquarters
Elstree, Hertfordshire
,
England, UK
Products Blood plasma
Owner
  • PRUK (2010–13)
  • BPL Holdings (2013–16)
Parent
Subsidiaries
  • BPL Therapeutics
  • BPL Plasma
Website bplgroup.com

Bio Products Laboratory Limited [1] (BPL) is a company involved in the manufacture of human blood plasma products, located in Elstree, Hertfordshire, England. It is run as a commercial business and supplies plasma derived products to the National Health Service in the UK as well as to markets in over 45 countries. [2]

Contents

BPL was a state owned organization and it was part of the U.K. National Health Service for most of its existence. On September 1, 2022, Permira and the Marcucci family acquired BPL and announced that their operations will be merged with another company acquired by the duo, Kedrion. [3]

History

The Blood Products Laboratory was established in 1954 as part of the Lister Institute of Preventive Medicine by the Medical Research Council. Lister purchased the Elstree site in 1902 and operated on the site until 1978.

During this time, Professor R. A.Kekwick, working at the Lister Institute undertook experimental and production work with A.S. McFarlane. The two scientists devised a process to clarify outdated blood plasma to render it suitable for transfusion. Laboratory testing was undertaken in the historic Queensbury Lodge, the site of Joseph Lister's laboratory.

In 1943, Kekwick was appointed Head of the Lister's Biophysics Division, Kekiwick established the Blood Filtration Unit and he and his team worked on methods of freeze-drying plasma and then of separating out proteins in blood plasma. These early products were used to meet the needs of the Armed Services and civilian establishments. In 1948 the Blood Filtration Unit came under the joint management of the Medical Research Council (MRC) and the Lister Institute, and the name was changed to the Blood Products Research Unit and it occupied the newly built laboratories (or ‘Building 25’). The aim of the Unit was directed towards the preparation of plasma fractions for clinical use

During the 1940s, Brinkhous and McFarlane discovered that transfusions using whole blood or plasma provided a means of FVIII replacement. Applications using this early discover were limited due to naturally low concentrations of this anti-haemophilic factor in blood and plasma and volume constraints in the circulatory system.

In 1954, the Government wished to establish a site for increased production of blood products. This followed on from the importance of blood in therapeutic medicine, the need for blood products during the Second World War (particularly the use of albumin) and the formation on 26 September 1946 of the National Blood Transfusion Service. It had also been discovered that a second form of haemophilia (Haemophilia B) existed, which was treatable with blood protein called Factor IX. An agreement was reached between the Government, MRC and the Lister Institute and the Blood Products Laboratory was established with funding from the Ministry of Health. Enlarged facilities for plasma fractionation and freeze-drying were established.

During the 1970s and 1980s it became apparent that Factor VIII products produced at the BPL site (and other products from other companies) had infected haemophiliacs with life-threatening viruses. [4] [5]

In 1991 it was renamed the Bio Products Laboratory to reflect the internal market in the National Health Service and in 1993 it became part of the National Blood Authority. BPL began cross-charging NHS hospitals for its products and limited competition in the international blood plasma market was permitted.

In 1998 the BPL began sourcing its plasma from the United States due to concerns over vCJD in the UK. In 2002 the Department of Health (DoH) formed DCI Biologicals Inc to purchase US company Life Resources Inc to supply all of the BPL's plasma. [6]

BPL became an operating division within new special health authority, NHS Blood and Transplant, in 2005. This placed BPL alongside the National Blood Service and the organ transplant division, a strategic partnership to safeguard blood, tissues and blood products.

On 31 December 2010 the BPL was vested into a limited company, Bio Products Laboratory Ltd, and ownership transferred to the DoH, with BPL Ltd and DCI Biologicals Inc brought under the same DoH holding company, Plasma Resources UK Ltd. [7]

On 18 July 2013 it was announced by Business Secretary Vince Cable that Bain Capital had bought 80% of Plasma Resources UK (PRUK) from the DoH for £230m, which included both BPL and DCI Biologicals. [8] [9]

The company was subsequently renamed BPL Holdings, with the original BPL site now called BPL Therapeutics and DCI named BPL Plasma. In 2018, when it was the sole owner, the Chinese group Creat had announced that it planned to integrate BPL's operations with German plasma product manufacturer Biotest.

Ownership

In 2013, Bain Capital acquired an 80% controlling interest in BPL, previously wholly owned by the UK Government. Three years later, the shareholders decided to sell BPL Holdings to Creat, an investment company based in Beijing that owns part of a plasma fractionator in China.

In 2022, Permira and Marcucci entered into an agreement to acquire and merge BPL and Kedrion operations into one venture. [10] As a result, the new company would inherit the shareholders of the companies involved, requiring the support of its co-investors.

In this case, FSI, CDP Equity and the other Kedrion shareholders had their shares transferred to the new company. In turn, to complete the agreement, the family group received the support of its co-investors, Ampersand Capital Partners and a wholly owned subsidiary of Abu Dhabi Investment Authority (ADIA).

See also

Related Research Articles

Transfusion medicine is the branch of medicine that encompasses all aspects of the transfusion of blood and blood components including aspects related to hemovigilance. It includes issues of blood donation, immunohematology and other laboratory testing for transfusion-transmitted diseases, management and monitoring of clinical transfusion practices, patient blood management, therapeutic apheresis, stem cell collections, cellular therapy, and coagulation. Laboratory management and understanding of state and federal regulations related to blood products are also a large part of the field.

<span class="mw-page-title-main">Blood plasma</span> Liquid component of blood

Blood plasma is a light amber-colored liquid component of blood in which blood cells are absent, however contains proteins and other constituents of whole blood in suspension. It makes up about 55% of the body's total blood volume. It is the intravascular part of extracellular fluid. It is mostly water, and contains important dissolved proteins, glucose, clotting factors, electrolytes, hormones, carbon dioxide, and oxygen. It plays a vital role in an intravascular osmotic effect that keeps electrolyte concentration balanced and protects the body from infection and other blood-related disorders.

<span class="mw-page-title-main">Fresh frozen plasma</span> Liquid portion of whole blood

Fresh frozen plasma (FFP) is a blood product made from the liquid portion of whole blood. It is used to treat conditions in which there are low blood clotting factors or low levels of other blood proteins. It may also be used as the replacement fluid in plasma exchange. Using ABO compatible plasma, while not required, may be recommended. Use as a volume expander is not recommended. It is administered by slow injection into a vein.

<span class="mw-page-title-main">Blood donation in England</span>

In England, blood and other tissues are collected by NHS Blood and Transplant (NHSBT). NHSBT Blood Donation was previously known as the National Blood Service until it merged with UK Transplant in 2005 to form a NHS special health authority. Other official blood services in the United Kingdom include the Northern Ireland Blood Transfusion Service, the Scottish National Blood Transfusion Service and the Welsh Blood Service.

Thomas Addis Jr. was a Scottish physician-scientist from Edinburgh who made important contributions to the understanding of how blood clots work. He was a pioneer in the field of nephrology, the branch of internal medicine that deals with diseases of the kidney. Addis described the pathogenesis of haemophilia in 1911 and was the first to demonstrate that normal plasma could correct the defect in haemophilia.

NHS Blood and Transplant is an executive non-departmental public body of the United Kingdom's Department of Health and Social Care. It was established on 1 October 2005 to take over the responsibilities of two separate NHS agencies: UK Transplant, founded by Dr. Geoffrey Tovey in 1972, and the National Blood Service. Its remit is to provide a reliable, efficient supply of blood, organs and associated services to the NHS. Since NHSBT was established, the organisation has maintained or improved the quality of the services delivered to patients, stabilised the rising cost of blood, and centralised a number of corporate services.

<i>Factor 8: The Arkansas Prison Blood Scandal</i> 2005 American film

Factor 8: The Arkansas Prison Blood Scandal is a feature-length documentary by Arkansas filmmaker and investigative journalist Kelly Duda. Through interviews and presentation of documents and footage, Duda alleges that in the 1970s and 1980s, the Arkansas prison system profited from selling blood plasma from inmates infected with viral hepatitis and HIV. The documentary contends that thousands of victims who received transfusions of blood products derived from these plasma products, Factor VIII, died as a result.

<span class="mw-page-title-main">Kelly Duda</span> American film director

Kelly Duda is an American filmmaker and activist from Arkansas best known for the 2005 documentary, Factor 8: The Arkansas Prison Blood Scandal.

<span class="mw-page-title-main">Lister Institute of Preventive Medicine</span>

The Lister Institute of Preventive Medicine, informally known as the Lister Institute, was established as a research institute in 1891, with bacteriologist Marc Armand Ruffer as its first director, using a grant of £250,000 from Edward Cecil Guinness of the Guinness family. It had premises in Chelsea in London, Sudbury in Suffolk, and Elstree in Hertfordshire, England. It was the first medical research charity in the United Kingdom. It was renamed the Jenner Institute in 1898 and then, in 1903, as the Lister Institute in honour of the great surgeon and medical pioneer, Dr Joseph Lister. In 1905, the institute became a school of the University of London.

<span class="mw-page-title-main">European Directorate for the Quality of Medicines & HealthCare</span> International organisation

The European Directorate for the Quality of Medicines & HealthCare (EDQM) is a Directorate of the Council of Europe that traces its origins and statutes to the Convention on the Elaboration of a European Pharmacopoeia.

The New Zealand Blood Service is the provider of blood services for New Zealand. The service is a Crown entity responsible to New Zealand's Parliament and is governed by a Board appointed by the Minister of Health.

Grifols, S.A. is a Spanish multinational pharmaceutical and chemical manufacturer. Principally a producer of blood plasma–based products, a field in which it is the European leader and largest worldwide, the company also supplies devices, instruments, and reagents for clinical testing laboratories.

<span class="mw-page-title-main">Contaminated blood scandal in the United Kingdom</span> The historical contamination of blood products in the UK with HIV and hepatitis C virus

In the 1970s and 1980s, a large number of people – most of whom had haemophilia – were infected with hepatitis C and HIV, the virus that leads to acquired immune deficiency syndrome (AIDS), as a result of receiving contaminated clotting factor products. In the United Kingdom, these were supplied by the National Health Service (NHS) and many of the products were imported from the US.

Professor Ralph Ambrose Kekwick. was a British biochemist who did pioneering work on human plasma fractionation, including the first production of Factor VIII.

The Welsh Blood Service is a division of Velindre University NHS Trust responsible for the collection of blood in Wales, and of the distribution of blood products to hospitals within the country, as well as other related functions.

Fereydoun Ala is an Iranian physician and academician, specialised in internal medicine, haematology, blood transfusion and haemostasis, who established the first Clinical Haematology Department, and the first Haemophilia Centre in Iran at the Tehran University Medical Faculty. He was the founder of the Iranian National Blood Transfusion Service (INBTS), a centralised, state-funded organisation, established in 1974, for the recruitment of healthy, voluntary, non-remunerated blood donors.

The Creat Group is a Chinese investment firm based in Beijing incorporated in 1992. It has expertise in the plasma industry and invests in healthcare and pharmaceuticals, manufacturing, energy, finance, natural resources, and real estate.

<i>A and Others v National Blood Authority and Another</i> Consumer law case involving claimants infected with hepatitis C

A and Others v National Blood Authority and Another, also known as the Hepatitis C Litigation, was a landmark product liability case of 2001 primarily concerning blood transfusions but also blood products or transplanted organs, all of which were infected with hepatitis C, where liability was established under the Consumer Protection Act 1987 and the Product Liability Directive (85/374/EEC) even in the absence of the ability to test to ascertain which blood transfusions were defective. The claimants were 114 individuals, six of whom were considered lead plaintiffs and given close consideration by the judge, Mr Justice Burton. Several of the claimants were minors who had become infected with Hepatitis C in the course of their treatment for leukaemia. The defendants were the National Blood Authority (NBA) and in respect of Wales, the Velindre NHS Trust, Cardiff. The court found that the UK government should have implemented measures to screen donated blood for HCV by March 1990, rather than September 1991, and that surrogate testing should have been introduced within the United Kingdom no later than 1 March 1988.

The Iranian Blood Transfusion Organization or acronymly IBTO is the highest and only decision-making authority in the field of supply and distribution of healthy blood and blood products in Iran. This organization was established in July 31, 1974.

<i>HIV Haemophilia Litigation</i> Legal action by haemophiliacs infected with HIV through blood products

The HIV Haemophilia Litigation [1990] 41 BMLR 171, [1990] 140 NLJR 1349 (CA), [1989] E N. 2111, also known as AMcG002, and HHL, was a legal claim by 962 plaintiffs, mainly haemophiliacs, who were infected with HIV as a result of having been treated with blood products in the late 1970s and early 1980s. The first central defendants were the then Department of Health, with other defendants being the Licensing Authority of the time, (MCA), the CSM, the CBLA, and the regional health authorities of England and Wales. In total, there were 220 defendants in the action.

References

  1. ↑ "Bio Products Laboratory Limited overview - Find and update company information - GOV.UK". Companies House . 11 August 2010. Retrieved 15 February 2024.
  2. ↑ "About BPL". Bio Products Laboratory. Archived from the original on 29 October 2015. Retrieved 21 October 2015.[ self-published source ]
  3. ↑ "Permira Funds and the Marcucci family complete investment in Kedrion and BPL and announce appointment of Ugo Di Francesco as CEO". Permira. Retrieved 29 December 2022.
  4. ↑ "Final Report: Chapter 19 - Production of Blood Products - Facilities". www.penroseinquiry.org.uk.
  5. ↑ Wheeler, Caroline (23 August 2015). "Sick children infected with HIV and used as guinea pigs as NHS said chimps 'too expensive'". Express.co.uk.
  6. ↑ Staff (17 December 2002). "UK buys 'safe' blood supply for NHS". BBC News World Edition. BBC News. Retrieved 21 October 2015.
  7. ↑ "Transfer of Bio Products Laboratory to Limited Co". Bio Products Laboratory. 5 January 2011. Archived from the original on 8 August 2011.[ self-published source ]
  8. ↑ "Bain Capital buys stake in UK government blood company". BBC News. 19 July 2013. Archived from the original on 19 July 2013. Retrieved 13 November 2020.
  9. ↑ "Bain Capital buys majority stake in Plasma Resources UK". The Guardian. 18 July 2013. Archived from the original on 30 July 2013. Retrieved 13 November 2020.
  10. ↑ "Permira Funds and the Marcucci family complete investment in Kedrion & BPL". Kedrion. Retrieved 29 December 2022.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.